Who is eligible for clinical trial NCT03218761?

Participants must meet protocol criteria for Postural Tachycardia Syndrome. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT03218761 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-10-08

POTS NET mRNA Functional Correlation With NET Activity (NCT03218761)

🔵 Active, Not Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Vanderbilt University Medical Center

🩺 Plain-English Summary (8th-Grade Level)

DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome (POTS) or make these patients more susceptible to certain medications. Quantified NET messenger RNA (mRNA) levels from a peripheral blood sample may be able to assess NET availability, which is simpler than older methods. This has not been validated against NET function. In this protocol, the investigators seek to assess whether these NET mRNA levels correlate with NET function. The investigators will assess the DHPG (NET dependent NE metabolite):NE ratio in POTS patients and control subjects from both plasma and urine samples.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (5 items).

Location: Vanderbilt University Medical Center — Nashville, Tennessee

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

• Postural Tachycardia Syndrome
Previously diagnosed with POTS
Control Subjects
Not diagnosed with POTS
Age between 13-80 years
Male and female subjects are eligible.
Able and willing to provide informed consent (if ≥18 years) or assent with parental consent (if age 13-17 years)

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
• Inability to give, or withdrawal of, informed consent
Use of serotonin-norepinephrine reuptake inhibitors (SNRI) or NET inhibitors within 1 month o These drugs pharmacologically block NET activity
Use of Tricyclic antidepressants within 1 week o Many tricyclic antidepressants pharmacologically block NET activity
Other factors which in the investigator's opinion would prevent the subject from completing the protocol.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Vanderbilt University Medical Center — Nashville, Tennessee

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗